Clinical trials: Myelogenous Leukemia, Acute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
- Trial name
- NCT05593185
- Testing
- Galinpepimut-S
- Sponsor
- Sellas Life Sciences Group
Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are…
- Trial name
- NCT00123487
- Testing
- dasatinib
- Where
- 119 sites in United States, Argentina and 30 more
- Volunteers
- 638 people
- Sponsor
- Bristol-Myers Squibb
AML, Adult
Natural Killer(NK) Cell Therapy in r/r AML
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in relapse/refractory Acute Myeloid Leukemia (AML).
- Trial name
- NCT05665114
- Testing
- QN-030a, Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemias, Advanced Hematological Malignancies
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells
Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation.
- Conditions
- Acute Myeloid Leukemias, Advanced Hematological Malignancies, Indication for Allogeneic Stem Cell Transplantation, no HLA-identical Donor Available
- Trial name
- NCT01220544
- Testing
- Haploidentical transplantation with donor NK cells
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Leukemia, Myeloid, Acute
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
- Trial name
- NCT06580106
- Testing
- Biospecimen samples
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Leukemia, Myeloid
Efficacy of FLAG Regimen for the Treatment of Patients With AML
The long-term efficacy of chemotherapy in patients with acute myeloid leukemia (AML) has been significantly improved in recent years.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Trial name
- NCT03600558
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University General Hospital
Acute Myeloid Leukemia
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).
- Trial name
- NCT05066165
- Testing
- Arm 1: NTLA-5001, Arm 2: NTLA-5001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- Intellia Therapeutics
Acute Myeloid Leukemia, Minimal Residual Disease Negativity
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
This phase II trial studies how well autologous stem cell transplant works in treating patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute myeloid leukemia.
- Trial name
- NCT03515707
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Etoposide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T…
- Trial name
- NCT03126864
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia
This phase I trial studies the best dose of azacitidine and to see how well it works with mitoxantrone hydrochloride and etoposide in treating older patients with acute myeloid leukemia that has a lower chance of responding to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia
- Trial name
- NCT01260714
- Testing
- Azacitidine, Etoposide, Laboratory Biomarker Analysis
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
NPMc+ AML
Oral Arsenic Trioxide for NPM1-mutated AML
A prospective open-label phase 2 study will be designed to assess the efficacy of oral arsenic trioxide plus azacitidine in preventing relapses in patients with NPM1-mutant AML.
- Trial name
- NCT04689815
- Testing
- Oral Arsenic Trioxide Formulation
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT01238211
- Testing
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride
- Where
- 65 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers
In this open-label, single-center, non-randomized patients with AML (Acute Myeloid Leukemia) and receiving all induction chemotherapy and consolidation consisting of cytarabine under the care usual for this pathology, will be…
- Trial name
- NCT03337516
- Testing
- Blood sampling, Genetic analysis
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acute Myeloid Leukemia
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
To evaluate the safety and tolerability of RC1012 injection infusion in AML Patients after Allo-HSCT
- Trial name
- NCT05858814
- Testing
- RC1012 injection (allo-DNT cells)
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
Several groups have demonstrated very low incidence of acute and chronic graft-versus-host disease (GVHD) with post-transplantation cyclophosphamide (PTCy) in haploidentical, unrelated and related allogeneic stem cell…
- Conditions
- Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia, Mixed-Lineage Acute Leukemias
- Trial name
- NCT02799147
- Testing
- Allogeneic stem cell transplantation, Fludarabine monophosphate, Busulfan
- Where
- Russia
- Volunteers
- 27 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Relapsed AML, Refractory AML
Phase 1 Study of Quizartinib
This is a dose escalation study to evaluate the safety, tolerability, and pharmacokinetics of quizartinib for Japanese acute myeloid leukemia (AML) subjects.
- Trial name
- NCT02675478
- Testing
- AC220
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
AlloHeme is a chimerism test service that utilizes NGS technology to analyze SNP loci to quantify donor and recipient cells by measuring genomic DNA.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- ACROBAT (NCT04635384)
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- CareDx
Acute Myeloid Leukemia
Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
Study Design: Treatment, Randomized, Open Label, Parallel Assignment This study is an open randomized and controlled trial aiming at assessing the efficacy and safety of Idarubicin (IDA) at different doses of 8mg/m2 and 10mg/m2…
- Trial name
- NCT02277847
- Testing
- Idarubicin(8mg/m2) and cytosine arabinoside, Idarubicin(10mg/m2), cytosine arabinoside
- Volunteers
- 400 people
- Sponsor
- Guangdong Provincial People's Hospital
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.